Study S001959

Efficacy of Exenatide-LAR Alone and in Combination With Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Uncontrolled Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02811484
Acronym: Dexlar
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: WITHDRAWN
Enrollment: 0
Start: 2016-06
Primary completion: 2018-06
Lead sponsor: Weill Medical College of Cornell University
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Exenatide-LAR plus Dapagliflozin placebo; DRUG:Exenatide-LAR plus Dapagliflozin; DRUG:Insulin Titration; BEHAVIORAL:Behavioral Therapy
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in HbA1c [baseline, 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.